aTyr Pharma Awaits FDA Response on Efzofitimod Phase 3
SAN DIEGO, September 1, 2026 aTyr Pharma, Inc. expects to receive a response from the U.S. Food and Drug...
fibrosis
Advertisement
Rectify Advances RTY-406 as Potential Disease-Modifying Therapy for PSC
Boston, Mass. – August 27, 2026 Rectify Pharmaceuticals presented the discovery and characterization of RTY-406, an oral, once-daily investigational...
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Skye Bioscience and Redx Pharma Plan $125M Merger
San Diego, California / Alderley Park, United Kingdom — August 14, 2026 Skye Bioscience, Inc. and Redx Pharma Limited...
aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches
SAN DIEGO, August 7, 2026 aTyr Pharma reported its second quarter 2026 results and announced a corporate restructuring designed...
Advertisements
Ono Pharma Partners with Mediar to Develop Novel Fibrosis Antibodies
OSAKA, Japan & BOSTON, Mass., August 6, 2026 Ono Pharmaceutical Co., Ltd. announced a drug discovery partnership and option...
Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
Contineum Therapeutics Publishes PIPE-791 Discovery Study
SAN DIEGO, June 30, 2026 Contineum Therapeutics, Inc. announced the publication of its scientific manuscript describing the discovery and...
Mediar Starts Phase 1 Trial of MTX-439 in CKD
BOSTON, Mass. | June 23, 2026 Mediar Therapeutics has announced that the first cohorts have been dosed in its...
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 in IPF
LA JOLLA, Calif., June 18, 2026 GRI Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
